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HospitalAbstract Objectives: Aim of this study was to prospectively determine the incidence and types of
emergency department (ED) visits and admissions due to drug related problems (DRPs) at Riyadh
Military Hospital (RMH), to assess the severity and preventability of these drug related admissions
or visits, and to identify the drugs and patient groups that are most commonly involved.
Method: Patients (n= 300) were selected randomly from patients presented to the ED during
the study period (one month). Computerized randomization program was used to select ten beds
daily on different areas and times. Patient was eligible to be included if either visited ED or admit-
ted through it due to DRPs.
Results: During the study period, 300 patients presented to ED were randomly selected with a
mean age of 47.8 ± 27.7 years. One hundred and forty of them were females (46.67%) and 160 were
male patients (53.33%). Of these 300 patients, 56 (18.7%) were presented to ED due to DRPs, and
244 (81.3%) patients were presented to ED due to non-drug related problems (NDRPs). About
ninety-three percent (n= 52) of the DRP group were exposed to hospital admission while only
7.1% (n= 4) were ED visits (Fig. 2). Male to female ratio in ED visits was 3:1 while it was
9.7:8.9 in the ED admission group.
18 M. Al-Ariﬁ et al.Conclusion: The prospective design of this study, sample size, and randomization increases the
likelihood that our estimates are accurate and increase the generalizability of our ﬁndings. Most
DRPs attributed to hospital admissions or visits were avoidable. Direct patient contact with phar-
macist and family physician was beneﬁcial in providing a safe and effective therapy. Corrective, pre-
ventive and educational strategies should concentrate on the most frequently reported populations,
diseases and medications. The study addresses the proper use of medications to ensure the best out-
comes of pharmacological interventions. Finally, more studies with longer duration focusing on
DRPs in Saudi Arabia are needed.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Nowadays medication use is increasing world-wide. (WHO,
2011; IMS, May 2011) The United States Food and Drug
Administration (USFDA) has approved more than 10000
drugs and Saudi National Formulary currently lists more than
6000 drugs. (IMS, April 2011; Bawazir et al., 2009) The rea-
sons may be the introduction of vast number of agents by
the advanced pharmaceutical industry in addition to the wide
spectrum of diseases that increased demands for intensifying
therapeutic challenges. (El-bagir, 1997) When people use med-
ications, any number of outcomes is possible. Most commonly,
the patient beneﬁts from pharmacotherapeutic interventions;
however, adverse events, ranging from minor side effects to
death, may occur. Any deviation from the intended beneﬁcial
effect of a medication results in a drug related problem (DRP).
(Johnson and Bootman, 1995).
One or more DRPs may develop in a given patient after the
initial drug therapy. Although many DRPs can be resolved
without a major impact on patient’s health, some of them
can be associated with signiﬁcant morbidity and mortality.
(Hepler and Strand, 1990; Classen et al., 1997) Hepler and
Strand deﬁned DRP as an event or circumstance involving
drug treatment that actually or potentially interferes with the
patients experiencing an optimum outcome of medical care.
(Hepler and Strand, 1990) They also classiﬁed DRPs into eight
general categories, which include untreated indication, treat-
ment without indication, improper drug selection, too little
drug, too much drug, noncompliance, adverse drug reaction
(ADR), and drug interaction (Strand et al., 1990).
It has been estimated that DRPs account for 17 million
emergency department (ED) visits and 8.7 million hospital
admissions annually in the United States. (Johnson and Boot-
man, 1995) Between 1995 and 2000, a probability model esti-
mated that costs associated with morbidity and mortality
secondary to DRPs have more than doubled fromUS$ 76.6 bil-
lion to more than US$ 177.4 billion. (Johnson and Bootman,
1995; Ernst andGrizzle, 2001) Although a considerable number
of studies were carried out determining the prevalence and inci-
dence of DRPs, studies published to date are unable to offer
precise information about the frequency of DRPs (McKenney
and Harrison, 1976). Winterstein and colleagues (2002) found
that 7.1% of hospital admissions result from DRPs, of which
59% were considered preventable. (Winterstein et al., 2002)
Zed etal. (2008) concluded thatDRPs counted for 12%of emer-
gency department visits and 68% of them were considered pre-
ventable. Rates of hospital admissions were higher and the
length of hospital stay appears to be longer among patients
whose visits were drug-related than among patients who pre-
sented for other reasons (Zed et al., 2008).Adverse drug reactions (ADRs) are an important cause of
morbidity and hospital admissions among the elderly (Nebeker
et al., 2004). A meta-analysis of observational studies revealed
that a considerable part of all hospital admissions is related to
ADRs. ADRs were mainly associated with age, sex, genetic
polymorphism, polypharmacy, and co-morbidity (Beijer and
de Blaey, 2002). The World Health Organization (WHO) de-
ﬁnes adverse drug reaction as any harmful, unintended reac-
tions to medicines that occur at doses normally used for
prophylaxis, diagnosis or treatment (WHO, 2008). Patterns
and types of drug use, misuse, and abuse vary widely across
communities, metro areas, regions, and states and these differ-
ing patterns across varied geographic areas must be under-
stood if appropriate prevention and treatment interventions
are to be undertaken. As the front line of pre hospital care
for individuals experiencing acute adverse consequences of
drug use, emergency departments (EDs) provide valuable in-
sights into the more serious aspects of certain patterns of drug
use (Ofﬁce of Applied Studies, 2010).
DRPs are common among older people after hospital
discharge and are relevant since they threaten patient’s safety.
(Nolan and O’Malley, 1988) In fact, the incidence of hospital
admissions and visits increased with age and especially elders
are more prone to drug related visits to hospitals, some studies
evaluated age as a variable. (Nolan and O’Malley, 1988) How-
ever, elderly patients may have multiple disease states and may
use a wide variety of drugs, increasing the potential for altered
responsiveness to drugs and a higher incidence of adverse ef-
fects compared with younger patients (Montamat et al.,
1989). In United States of America, estimates on drug-related
visits to hospital emergency departments (ED) are obtained
from the Drug Abuse Warning Network (DAWN), (Zed et
al., 2008) a public health surveillance system managed by
the Substance Abuse and Mental Health Services Administra-
tion (SAMHSA), U.S. Department of Health and Human
Services (HHS) and there was no such mechanism in Saudi
Arabia.
Although El-bagir (1997) found that DRPs constitute a
minor problem in Saudi Arabia, (El-bagir, 1997), Al Olah
and Al Thiab (2008) found that DRPs constitute serious prob-
lems in health care life of people in Saudi Arabia (Al Olah and
Al Thiab, 2008). However they agreed that there is a potential
for their increase in the future (El-bagir, 1997; Al Olah and Al
Thiab, 2008). Accordingly, the aim of our study is to prospec-
tively determine the incidence and types of ED visits and
admissions due to DRPs at Riyadh Military Hospital
(RMH). Secondary objectives include assessment of the sever-
ity and preventability of these drug related admissions or visits
and identifying the drugs and patient groups that are most
commonly involved.
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This prospective cohort observational study was conducted at
an ED in a military hospital (RMH), Riyadh, Saudi Arabia.
The study was carried out over a period of one month from
17th September to 16th October 2011 and was approved by
the Clinical Research Committee at RMH. RMH is a tertiary
referral hospital and the ED is physically divided into three
areas: ‘‘acute care’’ for major and serious problems, ‘‘stabi-
lized’’ for stable cases and ‘‘fast-track’’. Ethical approval was
obtained from clinical and research center at RMH.
According to ED statistics, about 10,000 patients are seen
monthly. A sample of 300 patients was selected randomly from
patients presented to the ED during the one month period
speciﬁed. Randomization was carried out by using a comput-
erized randomization program to select ten beds daily on dif-
ferent areas and times randomly. The patient is eligible to be
included if either visited ED or admitted through it due to
DRPs during the study period. The data were collected to
determine the incidence of admissions through the ED due
to DRPs, types of DRPs, and to assess the preventability of
admissions due to DRPs. All the required information were ta-
ken by one of the authors (Hanan) from the patient ﬁle and/or
patient interviewing using the data collection sheet designed
especially for this purpose (Fig. 1). These information include
chief complaint, past medical history, medication history, and
allergy status. Laboratory results (e.g. drug level) and results
of diagnostic tests were used when required.
The deﬁnitions used in this study, as described in similar
studies, (Al Olah and Al Thiab, 2008; Malhotra et al., 2001)
are as the following:
DRPs were deﬁned according to the Strand et al. classiﬁca-
tion mentioned earlier in the introduction (Strand et al., 1990).
Adverse drug reaction–any response that is noxious and unin-
tended and that occurs at doses normally used in humans forFigure 1 Data coprophylaxis, diagnosis, or treatment, excluding a failure to
accomplish the intended purpose (Karch and Lasagna, 1975).
A drug interaction is a medical problem resulting from a
drug–drug, drug–food, or drug–laboratory interaction; Drug
non-compliance–the extent to which the patient’s drug taking
behavior (in terms of taking medication) coincides with the
prescription (Haynes et al., 1979); Failure to receive drugs is
a medical problem that resulted from not receiving a drug
(e.g., for pharmaceutical, psychological, sociological, or eco-
nomic reasons); Improper drug selection was the taking of a
wrong drug (other than one prescribed by the physician); Drug
overdose was a medical problem treated with too much of the
correct drug (toxicity); Untreated indication was a medical
problem that required drug therapy (an indication for drug
use), but for which the patient was not receiving a drug;
Drug-related visits were deﬁned as ED visits caused by DRPs;
Drug related hospital admission–Admission caused by any
undesirable clinical manifestation that is consequent to and
caused by the administration of a particular drug. The clinical
manifestation may be a clinical sign, symptom, or abnormal
laboratory test or it may be a cluster of abnormal signs, symp-
toms, or tests. (McKenney and Harrison, 1976; Col et al.,
1990).
DRPs were deﬁned as ‘deﬁnitely preventable’ if the patient
(1) did not take a drug that is known to reduce or prevent the
symptoms according to the prescribed directions, (2) had a
known allergy, (3) had a disease for which the drug was con-
traindicated, and (4) took a drug that was not indicated, and
possibly avoidable if there is a failure to monitor by a physi-
cian at reasonable time intervals and inadequate monitoring
due to inability to see a physician (e.g., ﬁnancial difﬁculties)
(Nelson and Talbert, 1996). Severity was classiﬁed as mild
(laboratory abnormality or symptom not requiring treatment),
moderate (laboratory abnormality or symptom requiring treat-
ment or admission to hospital or resulting in nonpermanentllection sheet.
7.1 %
92.9 %
Visits
Admissions
Figure 2 Showing admissions and visits due to DRPs.
20 M. Al-Ariﬁ et al.disability), severe (abnormality or symptom that was life-
threatening or resulted in permanent disability) or fatal (Singh
et al., 2011). Simple statistics were used for analysis and
description of the data. All statistical parameters were ana-
lyzed by using Microsoft Excel 2007.Table 1 Description of the study population according to gender.
1- Demographic data of patients
Number (%)
Age (median/interquartile range) years
2- The incidence of drug related admissions or visits to RMH ED in both
DRPs Number (%)
NDRPs Number (%)
Total Number (%)
3- Admissions and visits to hospital in both groups, DRPs or NDRPs, acco
Admissions
NDRPs (DRPs)
Visits
NDRPs (DRPs)
Total
NDRPs (DRPs)
4- Admissions and visits to hospital due to DRPs according to gender
Admissions
Number
% within gender
% within admissions or visits
Visits
Number
% within gender
% within admissions or visits
Total
Number
% within gender
% within admissions or visits
5- Average number of medications in patients with DRPs according to gen
Number of medications Mean ± SD
6- Drug related problems in diﬀerent age groups for both sexes
Age group
Pediatric(<12 years) DRP number (% within Age group)
Adults (12–65 years) DRP number (% within Age group)
Elderly (>65 years) DRP number (% within Age group)
Total DRPs (%)3. Results
During the study period, 300 patients presented to EDwere ran-
domly selected with a median age of 51 with an interquartile
range of 47 years. One hundred and forty of them were females
(46.67%) and 160 were male patients (53.33%). Of these 300 pa-
tients, 56 (18.7%) were presented to ED due to DRPs, and 244
(81.3%) patients were presented to ED due to non drug related
problems (NDRPs). About ninety-three percent (n= 52) of the
DRP group were exposed to hospital admission while only
7.1% (n= 4) were ED visits (Fig. 2). Male to female ratio in
ED visits is 3:1 while it is 9.7:8.9 in the ED admission group (Ta-
ble 1). Additionally, Table 1 shows the distribution of the DRP
group into visits or admissions according to the age groups and
gender in addition to the incidence of both admissions and visits
according to the gender in both DRP and NDRP groups. Male
to female ratio is 8:7 in the study population and it is 1.5:1.3 in
the DRP group (Table 1).Male (%) Female (%) Total (%)
160 (53.33) 140 (46.67) 300
47/48.75 55/46.75 51 /47
groups, DRPs or NDRPs, according to the gender.
30 (53.57) 26 (46.43) 56 (18.67)
130(53.28) 114(46.72) 244(81.33)
160 (53.33) 140 (46.67) 300 (100)
rding to gender
139 (29) 112 (23) 251 (52)
21 (1) 28 (3) 49 (4)
160 (30) 140 (26) 300 (56)
29 23 52
96.7 88.5 92.9
55.8 44.2 100
1 3 4
3.3 11.5 7.1
25.0 75.0 100
30 26 56
100 100.0 100.0
53.6 46.4 100
der
5.96 ± 3.97 6.27 ± 4
5 (62.5) 3 (37.5) 8 (100)
13 (48.1) 14 (51.9) 27 (100)
12 (57.1) 9 (42.9) 21 (100)
30 (53.6) 26 (46.4) 56 (100)
Table 2 Incidence and age group classiﬁcation of drug related admissions or visits to RMH.
Group Visits number (% total visits) Admission number (% total admissions) Total number (% total)
1- The incidence of drug related admissions or visits to RMH ED
DRPs 4 (8.2%) 52 (20.7%) 56 (18.7%)
NDRPs 45 (91.8%) 199 (79.3%) 244 (81.3%)
Total 49 (100%) 251 (100%) 300 (100%)
Age group Visits (% within Age group) Admissions (% within Age group) Total (% within Age group)
2- Admissions and visits due to DRPs in diﬀerent age group
Pediatric(<12 years) 1 7 8
(12.5) (87.5) (100)
Adults (12–65 years) 3 24 27
(11.1) (88.9) (100)
Elderly (>65 years) 0 21 21
(0.0) (100.0) (100.0)
Total (%) 4 52 56
(7.1) (92.9) (100)
Emergency department visits and admissions due to drug related problems at Riyadh military hospital 21Out of 244 patients who were presented to ED for NDRPs,
only 18.4% (n= 45) were ED visits and 81.7% (n= 199) were
hospital admissions. The percentage of ED presentation due to
DRPs was high in adults of 48.1% (n= 27), followed by el-
derly of 37.50% (n= 21), and ﬁnally pediatrics of 14.29%
(n= 8) (Table 2).
The most common DRPs was due to adverse drug
reactions (ADRs) (30.4%) and patients’ non-compliance
(30.4%), followed by untreated indication (10.7%), then drug
interactions ; supratherapeutic and subtherapeutic dose (7.1%
for each), followed by improper drug selection (5.4%) and the
least contribution was for drug use without indication (1.8%).
The contribution of each of the DRPs to cause ED admissions
and visits in both male and female patients was shown in
Fig. 3. It is to be noted that ADR incidence is almost double
in female patients than male (11:6). Drug interactions pre-
sented only in elderly patients while non compliance and
ADRs are the most prominent DRPs in adults and pediatric
patients respectively. Importantly, ADRs in pediatric patients
contribute to 50% of all ADRs identiﬁed in the study subjects
(Table 3).
Regarding the preventability of DRPs, 32.1% of them were
considered deﬁnitely preventable, 53.6% were consideredSex M
Sex F
Figure 3 Types of DRPs with distribpossibly preventable and only 14.3% were considered deﬁ-
nitely non-preventable. All deﬁnitely non preventable DRPs
belong to ADRs while other DRPs are of varying degrees of
either preventable or possibly preventable. With regard to
the severity of DRPs, only 14.3% were considered severe,
48.2% were considered moderate and 37.5% were considered
mild. Non compliance is responsible for 37.5% of severe
DRPs, followed by untreated indication (25%) and 12.5%
for ADRs, drug interactions and supratherapeutic dose (Table
3). The most common drug groups associated with DRPs were
antihypertensive agents (21.5%), anticoagulants (14.3%),
immunosuppressants (12.5%) and chemotherapeutic agents
(10.7%) (Fig. 4). The most common diagnosis associated with
DRPs was hypertension (8.9%), diabetes mellitus (8.9%),
stroke (7.1%), urinary tract infection (5.4%), drug overdose
(5.4%), and febrile neutropenia (5.4%). The full list of diagno-
sis associated with DRPs is in Table 4. There is no signiﬁcant
difference between male and female groups with respect to
identiﬁed DRPs and average number of medications. The iden-
tiﬁed number of DRPs in the male group was 30 with the aver-
age number of medications of 5.96 ± 3.97 while in the female
group the identiﬁed number of DRPs is 26 and the average
number of medications is 6.27 ± 4 (Table 1).0
2
4
6
8
10
12
14
16
18
ution between males and females.
Table 3 Identiﬁed types and incidence of DRPs in ED at RMH and categorization according to gender, age group, preventability and severity.
DRPs Gender Age group Preventability Severity Total
Male Female Pediatric Adults Elderly Deﬁnitely preventable Deﬁnitely preventable Deﬁnitely preventable Mild Moderate Severe
Adverse drug reaction
% within DRPs 11 6 4 8 5 1 8 8 7 9 1 17
% within Group 64.7 35.3 5.9 47.1 47.1 41.2 52.9 5.9 100.0
42.3 20.0 50.0 29.6 23.8 5.6 100.0 26.7 33.3 33.3 12.5 30.4
Drug interaction 2 2 0 0 4 0 0 4 0 3 1 4
% within DRPs 50.0 50.0 0.0 0.0 100.0 0.0 75.0 25.0 100.0
% within Group 7.7 6.7 0.0 0.0 19.0 0.0 0.0 100.0 0.0 11.1 12.5 7.1
Drug use without indication 0 1 1 2 0 1 0 0 0 1 0 1
% within DRPs 0.0 100.0 100.0 0.0 0.0 0.0 100.0 0.0 100
% within Group 0.0 3.3 12.5 7.4 0.0 5.6 0.0 0.0 0.0 3.7 0.0 1.8
Improper drug selection 1 2 0 2 4 0 0 3 2 1 0 3
% within DRPs 33.3 66.7 0.0 0.0 100.0 66.7 33.3 0.0 100
% within Group 3.8 6.7 0.0 7.4 19.0 0.0 0.0 10.0 9.5 3.7 0.0 5.4
Non compliance 8 9 1 1 2 12 0 5 7 7 3 17
% within DRPs 47.1 52.9 70.6 0.0 29.4 41.2 41.2 17.6 100.0
% within Group 30.8 30.0 12.5 3.7 9.5 66.7 0.0 16.7 33.3 25.9 37.5 30.4
Subtherapeutic dosage
% within DRPs 1 3 1 3 0 0 0 4 2 2 0 4
% within Group 25.0 75.0 0.0 0.0 100.0 50.0 50.0 0.0 100.0
3.8 10.0 12.5 11.1 0.0 0.0 0.0 13.3 9.5 7.4 0.0 7.1
Supratherapeutic dosage 0 4 1 10 6 3 0 1 1 2 1 4
% within DRPs 0.0 100.0 75.0 0.0 25.0 25.0 50.0 25.0 100.0
% within Group 0.0 13.3 12.5 37.0 28.6 16.7 0.0 3.3 4.8 7.4 12.5 7.1
Untreated Indication 3 3 0 1 0 1 0 5 2 2 2 6
% within DRPs 50.0 50.0 16.7 0.0 83.3 33.3 33.3 33.3 100.0
% within Group 11.5 10.0 0.0 3.7 0.0 5.6 0.0 16.7 9.5 7.4 25.0 10.7
Total 26 30 8 27 21 18 8 30 21 27 8 56
% within DRPs 46.4 53.6 32.1 14.3 53.6 37.5 48.2 14.3 100.0
% within Group 100 100 100 100 100 100 100 100 100 100 100 100
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Figure 4 Identiﬁed drug groups associated with DRPs.
Table 4 Diagnosis associated with DRPs.
Diagnosis Number (%)
Bronchial asthma (BA) 1 (1.8)
Bulla pemphis 1 (1.8)
Congestive heart failure (CHF) 1 (1.8)
Diabetic foot/(DM) 1 (1.8)
Drug induced psychosis 1 (1.8)
Deep vein thrombosis (DVT) 1 (1.8)
Gallstone 1 (1.8)
Hodgkin lymphoma (HL) 1 (1.8)
Increase INR 1 (1.8)
Increase liver enzyme 1 (1.8)
Hypotension 1 (1.8)
Drug overdose 1 (1.8)
Persistent colic 1 (1.8)
Severe anemia 1 (1.8)
Transient ischemic attack (TIA) 1 (1.8)
Crohn’s disease (CD) 1 (1.8)
Drug overdose 2 (3.6)
Hyperglycemia/ (DM) 2 (3.6)
Hypoglycemia/ (DM) 2 (3.6)
Gastroenteritis 2 (3.6)
Gastrointestinal basidiobolomycosis (GIB) 2 (3.6)
Intracranial hemorrhage 2 (3.6)
Electrolyte disturbance 2 (3.6)
Multiple sclerosis (MS) 2 (3.6)
Neuroleptic malignant syndrome (NMS) 2 (3.6)
Sickle-cell anemia/Vaso-occlusive crisis 2 (3.6)
Seizure 2 (3.6)
Febrile neutropenia (FN) 3 (5.4)
Community acquired pneumonia (CAP) 3 (5.4)
Urinary tract infection (UTI) 3 (5.4)
Stroke 4 (7.1)
Hypertension 5 (8.9)
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Drug-related visits to the ED constitute a signiﬁcant problem
that contributes to the overall pressure on our health care sys-
tem. DRPs are a serious and costly issue (Johnson andBootman, 1995; Ernst and Grizzle, 2001) faced by health care
professionals and the health care system in Saudi Arabia (Al
Olah and Al Thiab, 2008). In recent years patient safety has
become a major concern for health care providers, and
medication management is one of its more relevant aspects.
Prospective studies on DRPs identiﬁed that approximately
10–28% of ED visits were due to DRPs but retrospective stud-
ies identiﬁed them in the range of 0.86–10.6%. (Winterstein
et al., 2002; Zed et al., 2008; Budnitz et al., 2006; Patel and
Zed, 2002) This considerable variation in the incidence of
drug-related visits to hospital emergency room is due to vari-
able objectives, deﬁnitions and methods applied to the studies
(Patel and Zed, 2002; Juntti-Patinen et al., 2006). Our study re-
sults show that drug-related hospital admissions and visits ac-
count for 18.7% of total ED admissions and visits (92.9% of
them admissions and 7.1% visits) which means drug related
admissions constitute 17.3% of total ED admissions. Hospital
admissions of patients who visited the ED with a drug-related
problem were estimated to be 8.6–24.2% and were associated
with increased costs to health care systems (Patel and Zed,
2002). Moreover, the incidence of drug related hospital admis-
sions in Saudi Arabia is increasing since El-Bagir (1997),
Al-Olah et al. (2008) and our study reported the incidence of
drug related hospital admissions to be 11%, 14.7% and
17.3% respectively (El-bagir, 1997; Al Olah and Al Thiab,
2008). The results of this study are consistent with interna-
tional studies suggesting that the incidence of admissions
through the ED due to DRPs in RMH is similar to that in
other countries (Johnson and Bootman, 1995; Nelson and
Talbert, 1996; Einarson, 1993; Ives et al., 1987; Hanlon
et al., 2004). This brings to attention the importance of medi-
cine management and reinforcing the patient centered care to
ensure the best outcomes of pharmacotherapeutic interven-
tions. The need for direct patient contact by pharmacists and
family physicians is obvious and a collaborative and interdisci-
plinary patient centered care model is most beneﬁcial to pro-
viding safe and effective therapy (Tom, 2001).
The most often encountered DRPs were patient’s non-com-
pliance and ADRs which are consistent with the previous na-
tional study and international studies (Al Olah and Al Thiab,
2008; Patel and Zed, 2002). Moreover, both non-compliance
and ADRs have been consistently cited as the primary reasons
for drug related morbidity regardless of study setting. In our
study, 32.1% of DRPs were assessed to be deﬁnitely prevent-
able which is much less than those previously reported by
Al-Olah and colleague (83%) that can be explained by meth-
odological differences in both studies (Al Olah and Al Thiab,
2008). Possibly preventable DRPs were 53.6% which is compa-
rable to international studies in developed countries which sug-
gest that approximately 50% of DRPs were preventable
(Nelson and Talbert, 1996).
The study revealed that the incidence of adult hospital
admissions due to DRPs is higher if compared to elderly and
pediatrics. However, elderly population is only 2.9 % of the
Saudi population (UN, 2006) which means that the incidence
is much higher among elderly population. Elderly patients
may have multiple disease states and may use a wide variety
of drugs, increasing the potential for altered responsiveness
to drugs and a higher incidence of adverse effects compared
to younger patients. (Malhotra et al., 2001; Montamat et al.,
1989) Moreover, a substantial proportion of the elderly
patients is non-compliant; estimates varying from 26% to
24 M. Al-Ariﬁ et al.59% (Malhotra et al., 2001). However, better patient educa-
tion about drug side effects and the pros and cons of uncon-
ventional therapies can help in decreasing noncompliance.
The high number of drugs per patient means that the like-
lihood of DRPs increases as the number of drugs prescribed
rises which assures the direct relation between the number of
drugs prescribed and both ED visits and admissions due to
DRPs (Malhotra et al., 2001). Importantly, a greater number
of medications would increase the potential for adverse drug
reactions and poor adherence. Therefore, minimizing the total
number of medications that individual patients receive might
therefore reduce drug-related visits to the emergency depart-
ment. This is consistent with the well known principle of geri-
atric clinical pharmacology: prescribe simpler regimens with
fewer pills to be taken each day.
The pattern of severity of the patient outcomes associated
with drug-related hospitalization is different from previous
work (Singh etal., 2011). Singh et al. found that about 75% con-
sidered moderate where, in our study, it is only about the half of
identiﬁed DRPs. In contrary, our study showed a higher per-
centage of severe outcomes (14.3%) compared to only 6.78%
in Singh et al. study. Moreover, these severe outcomes were no-
ticed with both non compliance and untreated indications
which necessitate enforcing the possible corrective actions.
Based on our study, particular effort should be made to prevent
DRPs in hypertensive patients, stroke patients, diabetic pa-
tients, and in cases of seizure and fever in neutropenic patients.
In addition, enforced counseling and education are needed for
patients receiving antihypertensives, anticoagulants, chemo-
therapy, and immunosuppressant and over the counter drugs
(OTC) and study involved patients presented at ED.
5. Conclusion
The prospective design of this study, sample size, and random-
ization increases the likelihood that our estimates are accurate
and increase the generalizability of our ﬁndings. Most DRPs
attributed to hospital admissions or visits were classiﬁed avoid-
able. Direct patient contact with pharmacist and family physi-
cian is beneﬁcial to providing a safe and effective therapy.
Corrective, preventive and educational strategies should con-
centrate on the most frequently reported populations, diseases
and medications. The study addresses the proper use of medi-
cations to ensure the best outcomes of pharmacological inter-
ventions. Finally, more studies with longer duration focusing
on DRPs in Saudi Arabia are needed.
6. Limitations
A signiﬁcant number of patients with minor DRPs have been
missed from the outpatient department and other major
departments. In addition, short duration of the study and
the fact that all data were collected in a single institution are
the limitations of our work.
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